Jarosław Zalewski

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The dynamic evolution of therapeutic options including the use of vitamin K antagonists (VKA), non-vitamin K oral anticoagulants (NOAC), more potent antiplatelet drugs as well as new generation drug-eluting stents could lead to the view that the current recommendations on the management of patients with percutaneous coronary intervention (PCI) requiring(More)
  • 1